- Home
- JANX
as 01-21-2025 4:00pm EST
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 3.0B | IPO Year: | 2021 |
| Target Price: | $83.09 | AVG Volume (30 days): | 971.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.79 - $71.71 | Next Earning Date: | 03-07-2025 |
| Revenue: | $13,049,000 | Revenue Growth: | 54.12% |
| Revenue Growth (this year): | 39.66% | Revenue Growth (next year): | -72.46% |
Stock Insider Trading Activity of Janux Therapeutics Inc. (JANX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Campbell David Alan | JANX | President and CEO | Jan 7 '25 | Sell | $60.00 | 5,000 | $300,004.00 | 293,054 | |
| Meyer Andrew Hollman | JANX | Chief Business Officer | Jan 2 '25 | Sell | $55.63 | 13,334 | $731,785.25 | 92,551 | |
| Campbell David Alan | JANX | President and CEO | Dec 24 '24 | Sell | $56.19 | 25,000 | $1,404,805.00 | 293,054 | |
| Campbell David Alan | JANX | President and CEO | Dec 3 '24 | Sell | $67.00 | 15,000 | $1,005,000.00 | 293,054 | |
| Campbell David Alan | JANX | President and CEO | Nov 25 '24 | Sell | $51.74 | 25,000 | $1,289,878.73 | 293,054 | |
| Campbell David Alan | JANX | President and CEO | Oct 28 '24 | Sell | $53.58 | 25,000 | $1,338,558.90 | 293,054 |
Latest Janux Therapeutics Inc. News
JANX Breaking Stock News: Dive into JANX Ticker-Specific Updates for Smart Investing
Business Wire
2 months ago
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
MT Newswires
2 months ago
Janux Therapeutics Prices $350 Million Offering of Shares, Warrants
Business Wire
2 months ago
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Motley Fool
2 months ago
Why Janux Therapeutics Crushed the Market Today
Zacks
2 months ago
JANX Stock Hits Record High on Prostate Cancer Study Data
MT Newswires
2 months ago
Janux Therapeutics Launches $300 Million Offering
Investor's Business Daily
2 months ago
Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride
Business Wire
2 months ago
Janux Therapeutics Announces Proposed Public Offering
Compare JANX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JANX Janux Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.